Alnylam Pharmaceuticals, Inc.
ALNY
$292.03
$7.192.52%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 6.39% | -12.17% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 6.39% | -12.17% | |||
| Cost of Revenue | -21.14% | 33.76% | |||
| Gross Profit | 15.28% | -20.93% | |||
| SG&A Expenses | -0.87% | 1.02% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -6.92% | 9.56% | |||
| Operating Income | 103.95% | -64.21% | |||
| Income Before Tax | 37.56% | -32.57% | |||
| Income Tax Expenses | 161.95% | -108.68% | |||
| Earnings from Continuing Operations | 10.50% | -25.75% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 10.50% | -25.75% | |||
| EBIT | 103.95% | -64.21% | |||
| EBITDA | 94.31% | -61.96% | |||
| EPS Basic | 9.95% | -26.20% | |||
| Normalized Basic EPS | 80.78% | -56.40% | |||
| EPS Diluted | 10.29% | -25.67% | |||
| Normalized Diluted EPS | 79.12% | -55.79% | |||
| Average Basic Shares Outstanding | 0.50% | 0.60% | |||
| Average Diluted Shares Outstanding | 1.43% | -0.78% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||